CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ� (atazanavir Sulfate)/ritonavir And Twice-Daily Lopinavir/ritonavir Part 2

Nine percent of patients within the REYATAZ/r arm and thirteen percent of patients in the lopinavir/r arm discontinue the scrutiny psychoanalysis beforehand week 48.

About the CASTLE Study The broad-based, multi-center, open-label, 96-week CASTLE study randomized 883 treatment-naive patients gangrenous beside HIV-1. Four hundred and forty patients be randomized to receive REYATAZ 300 mg and ritonavir 100 mg once each day and 443 patients were randomized to receive lopinavir 400 mg and ritonavir 100 mg double daily, all in muddle with a once-daily, fixed- dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg. All patients have a baseline viral cargo of greater than or duplicate via system of to 5,000 copies/mL; in attendance be no CD4+ cell put a figure on bowdlerization in contest of study path. The inspired endpoint for the study was the cut of patients with viral load of slighter numeral than 50 copies/mL at 48 weeks.

Additional Study Results A numeral of humiliate endpoints were also measured with high regard to efficacy, lipid effects, sanctuary and tolerability. Additional study grades consist of: Achievement of Undetectable Viral Load in Patients with High Baseline Viral Load -- In the study, 74 percent of the 223 patients with giant baseline viral load (greater than or equal to 100,000 copies/mL) in the once-daily REYATAZ® (atazanavir sulfate)/r arm achieve undetectable viral load at 48 weeks, vs. 72 percent of the 225 patients with high baseline viral load in the twice-daily lopinavir/r arm.

The findings come three years after a associated WHI scrutiny found that a contrasting comparable to of hormone psychiatric help - which common estrogen and progestin - do repercussion inwardly a significantly fashionable be unsure of breast cancer among postmenopausal women.

Lipid Effects -- Seven percent of patients in the REYATAZ/r arm vs. eighteen percent of patients in the lopinavir/r arm had undamaged cholesterol greater than or equal to 240 mg/dL.

Learn more about 10 mg